Study S001174

Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01511393
Study type: OBSERVATIONAL
Status: ENROLLING_BY_INVITATION
Enrollment: 6750
Start: 2012-01
Primary completion: 2039-12
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Medullary Thyroid Carcinoma; Weight Management
Interventions: OTHER:No treatment given
Results posted: FALSE
Individual participant data sharing: UNDECIDED
Secondary identifiers: OTHER:U1111-1125-4362

Registered primary outcomes

Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market. [Up to 15 years]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010803	A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting. Major-Pedersen A, Pharmacoepidemiology and drug safety	2021	Nonrandomized study	PMID 33179845 DOI	cites ClinicalTrials.gov:NCT01511393; registry reference DERIVED:33179845